Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Daniel L Gustafson

TitleAffiliate
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-U of Colo Cancer Center
Phone303/315-0755

    Collapse Research 
    Collapse research activities and funding
    F32CA064039     (GUSTAFSON, DANIEL L)May 1, 1994
    NIH/NCI
    MITOMYCIN C SENSITIVITY IN CHO CELL MUTANTS AND HYBRIDS
    Role: Principal Investigator

    K01CA075955     (GUSTAFSON, DANIEL L)Jul 1, 1998 - Jun 30, 2003
    NIH/NCI
    PREDICTIVE MODELS FOR COMBINATION CANCER CHEMOTHERAPY
    Role: Principal Investigator

    R01CA101988     (GUSTAFSON, DANIEL L)Jan 1, 2005 - Jun 30, 2009
    NIH/NCI
    Dual Compartmental Targeting of Cancer
    Role: Principal Investigator

    R01CA190170     (THORBURN, ANDREW M)Jul 1, 2015 - Jun 30, 2020
    NIH/NCI
    Therapeutic targeting of autophagy-dependent cancer
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Zajic LB, Herndon AK, Sieberg LG, Caress AL, Morgan PK, Hansen RJ, Wittenburg LA, Gustafson DL, Quimby JM. Assessment of absorption of transdermal ondansetron in normal research cats. J Feline Med Surg. 2017 Jan 01; 1098612X16688807. PMID: 28112563.
      View in: PubMed
    2. Worley DR, Hansen RJ, Wittenburg LA, Chubb LS, Gustafson DL. Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats. Anticancer Res. 2016 10; 36(10):5071-5078. PMID: 27798866.
      View in: PubMed
    3. Benson KK, Zajic LB, Morgan PK, Brown SR, Hansen RJ, Lunghofer PJ, Wittenburg LA, Gustafson DL, Quimby JM. Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study. J Feline Med Surg. 2016 Sep 09. PMID: 27613493.
      View in: PubMed
    4. Morrow JJ, Mendoza A, Koyen A, Lizardo MM, Ren L, Waybright TJ, Hansen RJ, Gustafson DL, Zhou M, Fan TM, Scacheri PC, Khanna C. mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. Clin Cancer Res. 2016 Dec 15; 22(24):6129-6141. PMID: 27342399.
      View in: PubMed
    5. Tabakoff B, Ren W, Vanderlinden L, Snell LD, Matheson CJ, Wang ZJ, Levinson R, Smothers CT, Woodward JJ, Honse Y, Lovinger D, Rush AM, Sather WA, Gustafson DL, Hoffman PL. A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2016 Aug 05; 784:1-14. PMID: 27158117; PMCID: PMC5024723 [Available on 08/05/17].
    6. Fowles JS, Brown KC, Hess AM, Duval DL, Gustafson DL. Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. BMC Bioinformatics. 2016 Feb 19; 17:93. PMID: 26892349; PMCID: PMC4759767.
    7. LeBlanc AK, Breen M, Choyke P, Dewhirst M, Fan TM, Gustafson DL, Helman LJ, Kastan MB, Knapp DW, Levin WJ, London C, Mason N, Mazcko C, Olson PN, Page R, Teicher BA, Thamm DH, Trent JM, Vail DM, Khanna C. Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. Sci Transl Med. 2016 Feb 03; 8(324):324ps5. PMID: 26843188.
      View in: PubMed
    8. Larson JC, Allstadt SD, Fan TM, Khanna C, Lunghofer PJ, Hansen RJ, Gustafson DL, Legendre AM, Galyon GD, LeBlanc AK, Martin-Jimenez T. Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. Am J Vet Res. 2016 Jan; 77(1):65-71. PMID: 26709938.
      View in: PubMed
    9. Gustafson DL, Fowles JS, Brown KC, Theodorescu D. Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay Drug Dev Technol. 2015 Dec; 13(10):623-7. PMID: 26690765; PMCID: PMC4692133 [Available on 12/01/16].
    10. Watson MK, Wittenburg LA, Bui CT, Jarosz KA, Gustafson DL, Johnston MS. Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2015 Nov; 76(11):946-51. PMID: 26512539.
      View in: PubMed
    11. Bachtel JC, Pendergraft JS, Rosychuk RA, Gustafson DL, Hansen RJ, Lunghofer PJ. Comparison of the stability and pharmacokinetics in dogs of modified ciclosporin capsules stored at -20°C and room temperature. Vet Dermatol. 2015 Aug; 26(4):228-e50. PMID: 26178603.
      View in: PubMed
    12. Pilon JL, Clausen DJ, Hansen RJ, Lunghofer PJ, Charles B, Rose BJ, Thamm DH, Gustafson DL, Bradner JE, Williams RM. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol. 2015 Apr; 75(4):671-82. PMID: 25616967; PMCID: PMC4368451.
    13. Griffenhagen GM, Rezende ML, Gustafson DL, Hansen RJ, Lunghofer PJ, Mama KR. Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. Vet Anaesth Analg. 2015 Sep; 42(5):472-83. PMID: 25327817.
      View in: PubMed
    14. Kendall LV, Hansen RJ, Dorsey K, Kang S, Lunghofer PJ, Gustafson DL. Pharmacokinetics of sustained-release analgesics in mice. J Am Assoc Lab Anim Sci. 2014 Sep; 53(5):478-84. PMID: 25255070; PMCID: PMC4181689.
    15. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy. 2014 Aug; 10(8):1415-25. PMID: 24991836; PMCID: PMC4203518.
    16. Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor. BMC Vet Res. 2014 May 06; 10:105. PMID: 24885200; PMCID: PMC4049511.
    17. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014 May 01; 74(9):2579-90. PMID: 24590058; PMCID: PMC4008672.
    18. Thorburn A, Thamm DH, Gustafson DL. Autophagy and cancer therapy. Mol Pharmacol. 2014 Jun; 85(6):830-8. PMID: 24574520; PMCID: PMC4014668.
    19. Hudachek SF, Gustafson DL. Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of mice. Anticancer Drugs. 2013 Oct; 24(9):958-68. PMID: 23928571; PMCID: PMC4694043.
    20. Hackett ES, Mama KR, Twedt DC, Gustafson DL. Evaluation of antioxidant capacity and inflammatory cytokine gene expression in horses fed silibinin complexed with phospholipid. Am J Vet Res. 2013 Oct; 74(10):1333-9. PMID: 24066918.
      View in: PubMed
    21. Hackett ES, Mama KR, Twedt DC, Gustafson DL. Pharmacokinetics and safety of silibinin in horses. Am J Vet Res. 2013 Oct; 74(10):1327-32. PMID: 24066917.
      View in: PubMed
    22. Wong OA, Hansen RJ, Ni TW, Heinecke CL, Compel WS, Gustafson DL, Ackerson CJ. Structure-activity relationships for biodistribution, pharmacokinetics, and excretion of atomically precise nanoclusters in a murine model. Nanoscale. 2013 Nov 07; 5(21):10525-33. PMID: 24057086; PMCID: PMC3870010.
    23. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4149-62. PMID: 23757356; PMCID: PMC3905307.
    24. Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014 Jan; 13(1):46-53. PMID: 23757319; PMCID: PMC3866213.
    25. Hudachek SF, Gustafson DL. Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice. J Pharmacokinet Pharmacodyn. 2013 Aug; 40(4):437-49. PMID: 23616082; PMCID: PMC4292804.
    26. Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG. Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol. 2013; 4:22. PMID: 23524533; PMCID: PMC3605511.
    27. Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One. 2013; 8(3):e58089. PMID: 23520486; PMCID: PMC3592886.
    28. De Miranda BR, Miller JA, Hansen RJ, Lunghofer PJ, Safe S, Gustafson DL, Colagiovanni D, Tjalkens RB. Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease. J Pharmacol Exp Ther. 2013 Apr; 345(1):125-38. PMID: 23318470.
      View in: PubMed
    29. Hudachek SF, Gustafson DL. Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans. J Pharmacokinet Pharmacodyn. 2013 Apr; 40(2):157-76. PMID: 23315145; PMCID: PMC3897212.
    30. Mitchell LA, Hansen RJ, Beaupre AJ, Gustafson DL, Dow SW. Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. Int Immunopharmacol. 2013 Feb; 15(2):357-63. PMID: 23246255; PMCID: PMC3875337.
    31. Venable RO, Worley DR, Gustafson DL, Hansen RJ, Ehrhart EJ, Cai S, Cohen MS, Forrest ML. Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas. Am J Vet Res. 2012 Dec; 73(12):1969-76. PMID: 23176425; PMCID: PMC3778682.
    32. Hackett ES, Gustafson DL. Alterations of drug metabolism in critically ill animals. Vet Clin North Am Small Anim Pract. 2011 Jul; 41(4):805-15, vii. PMID: 21757094.
      View in: PubMed
    33. da Silva EG, Gionfriddo JR, Hudachek SF, Gustafson DL, Olea-Popelka FJ, Scofield VL, Powell CC, Hill AE. Evaluation of the ocular penetration of topical alpha-luminol (Galavit®/GVT®). Vet Ophthalmol. 2011 May; 14(3):180-5. PMID: 21521442.
      View in: PubMed
    34. Wittenburg LA, Gustafson DL. Optimizing preclinical study design in oncology research. Chem Biol Interact. 2011 Apr 25; 190(2-3):73-8. PMID: 21296059.
      View in: PubMed
    35. Ellis BK, Stanford JA, Goodman D, Stafford CP, Gustafson DL, Beauchamp DA, Chess DW, Craft JA, Deleray MA, Hansen BS. Long-term effects of a trophic cascade in a large lake ecosystem. Proc Natl Acad Sci U S A. 2011 Jan 18; 108(3):1070-5. PMID: 21199944; PMCID: PMC3024674.
    36. Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):849-60. PMID: 21131552; PMCID: PMC3867298.
    37. Hansen RJ, Samber BJ, Gustafson DL. Rapid and sensitive LC-MS/MS method for determination of felbamate in mouse plasma and tissues and human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Dec 15; 878(32):3432-6. PMID: 21081288; PMCID: PMC4278804.
    38. Hudachek SF, Gustafson DL. Customized in silico population mimics actual population in docetaxel population pharmacokinetic analysis. J Pharm Sci. 2011 Mar; 100(3):1156-66. PMID: 20803616.
      View in: PubMed
    39. Wittenburg LA, Gustafson DL, Thamm DH. Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res. 2010 Oct 01; 16(19):4832-42. PMID: 20705615; PMCID: PMC2948605.
    40. Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, Vail DM, Nuckolls K, Osborne T, Yalkowsy S, Gustafson D, Yu Y, Cao L, Khanna C. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One. 2010 Jun 08; 5(6):e11013. PMID: 20543980; PMCID: PMC2882366.
    41. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 Jun 01; 70(8):848-55. PMID: 20127732.
      View in: PubMed
    42. Denton CL, Gustafson DL. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol. 2011 Feb; 67(2):349-60. PMID: 20407895; PMCID: PMC4332869.
    43. Thamm DH, Kurzman ID, Clark MA, Ehrhart EJ, Kraft SL, Gustafson DL, Vail DM. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation. Clin Cancer Res. 2010 Mar 01; 16(5):1498-508. PMID: 20160058.
      View in: PubMed
    44. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. 2011 Apr; 29(2):340-6. PMID: 20084425; PMCID: PMC4331064.
    45. Leong S, Cohen RB, Gustafson DL, Langer CJ, Camidge DR, Padavic K, Gore L, Smith M, Chow LQ, von Mehren M, O'Bryant C, Hariharan S, Diab S, Fox NL, Miceli R, Eckhardt SG. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol. 2009 Sep 10; 27(26):4413-21. PMID: 19652058.
      View in: PubMed
    46. Hudachek SF, Eckhardt SG, Hicks B, Gustafson DL. Population pharmacokinetic model of PI-88, a heparanase inhibitor. Cancer Chemother Pharmacol. 2010 Mar; 65(4):743-53. PMID: 19633850.
      View in: PubMed
    47. Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L. A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther. 2008 Dec; 7(12):3685-94. PMID: 19074845; PMCID: PMC2813692.
    48. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, Henry C, Owen N, Madsen R, Dhand R. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv. 2008 Sep; 21(3):255-68. PMID: 18759657.
      View in: PubMed
    49. Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther. 2008 Sep; 7(9):3006-17. PMID: 18790781; PMCID: PMC2673509.
    50. Chow LQ, Gustafson DL, O'Bryant CL, Gore L, Basche M, Holden SN, Morrow MC, Grolnic S, Creese BR, Roberts KL, Davis K, Addison R, Eckhardt SG. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol. 2008 Dec; 63(1):65-74. PMID: 18320191; PMCID: PMC2813677.
    51. Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci. 2008 Jan; 97(1):237-50. PMID: 17721944.
      View in: PubMed
    52. Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol. 2008 Sep; 62(4):605-20. PMID: 18030469.
      View in: PubMed
    53. Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res. 2007 Nov 01; 13(21):6450-8. PMID: 17975157.
      View in: PubMed
    54. Lana S, U'ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med. 2007 Jul-Aug; 21(4):764-9. PMID: 17708397.
      View in: PubMed
    55. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007 May 01; 13(9):2768-76. PMID: 17473210.
      View in: PubMed
    56. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008 Feb; 61(2):179-88. PMID: 17393165.
      View in: PubMed
    57. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 01; 12(23):7117-25. PMID: 17145836.
      View in: PubMed
    58. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 Apr; 25(2):139-46. PMID: 17077998.
      View in: PubMed
    59. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006 Sep 15; 12(18):5471-80. PMID: 17000682.
      View in: PubMed
    60. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 2006 Oct; 70(4):1194-203. PMID: 16825487.
      View in: PubMed
    61. Gustafson DL, Bradshaw-Pierce EL, Merz AL, Zirrolli JA. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. J Pharmacol Exp Ther. 2006 Aug; 318(2):872-80. PMID: 16644900.
      View in: PubMed
    62. Selting KA, Ogilvie GK, Gustafson DL, Long ME, Lana SE, Walton JA, Hansen RA, Turner AS, Laible I, Fettman MJ. Evaluation of the effects of dietary n-3 fatty acid supplementation on the pharmacokinetics of doxorubicin in dogs with lymphoma. Am J Vet Res. 2006 Jan; 67(1):145-51. PMID: 16426224.
      View in: PubMed
    63. Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I, Raben D. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):33-7. PMID: 16377413.
      View in: PubMed
    64. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005 Nov 01; 65(21):10006-15. PMID: 16267026.
      View in: PubMed
    65. Thienelt CD, Bunn PA, Hanna N, Rosenberg A, Needle MN, Long ME, Gustafson DL, Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005 Dec 01; 23(34):8786-93. PMID: 16246975.
      View in: PubMed
    66. Zirrolli JA, Bradshaw EL, Long ME, Gustafson DL. Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. J Pharm Biomed Anal. 2005 Sep 15; 39(3-4):705-11. PMID: 15935603.
      View in: PubMed
    67. Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol. 2005 Sep; 56(3):248-54. PMID: 15856231.
      View in: PubMed
    68. Gustafson DL, Merz AL, Long ME. Pharmacokinetics of combined doxorubicin and paclitaxel in mice. Cancer Lett. 2005 Apr 08; 220(2):161-9. PMID: 15766591.
      View in: PubMed
    69. Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biol Blood Marrow Transplant. 2005 Apr; 11(4):297-306. PMID: 15812395.
      View in: PubMed
    70. Dunn JS, Freed BM, Gustafson DL, Stringer KA. Inhibition of human neutrophil reactive oxygen species production and p67phox translocation by cigarette smoke extract. Atherosclerosis. 2005 Apr; 179(2):261-7. PMID: 15777540.
      View in: PubMed
    71. Stringer KA, Freed BM, Dunn JS, Sayers S, Gustafson DL, Flores SC. Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic Biol Med. 2004 Nov 15; 37(10):1527-33. PMID: 15477004.
      View in: PubMed
    72. Witta SE, Gustafson DL, Pierson AS, Menter A, Holden SN, Basche M, Persky M, O'Bryant CL, Zeng C, Baron A, Long ME, Gibbs A, Kelly K, Bunn PA, Chan DC, Pallansch P, Eckhardt SG. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clin Cancer Res. 2004 Nov 01; 10(21):7229-37. PMID: 15534096.
      View in: PubMed
    73. Stringer KA, Dunn JS, Gustafson DL. Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene. Clin Exp Pharmacol Physiol. 2004 May-Jun; 31(5-6):327-30. PMID: 15191406.
      View in: PubMed
    74. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol. 2004 May; 65(5):1238-47. PMID: 15102952.
      View in: PubMed
    75. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol. 2003 Aug; 52(2):159-66. PMID: 12759775.
      View in: PubMed
    76. Ou YC, Conolly RB, Thomas RS, Gustafson DL, Long ME, Dobrev ID, Chubb LS, Xu Y, Lapidot SA, Andersen ME, Yang RS. Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci. 2003 Jun; 73(2):301-14. PMID: 12700395.
      View in: PubMed
    77. Gustafson DL, Siegel D, Rastatter JC, Merz AL, Parpal JC, Kepa JK, Ross D, Long ME. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo. J Pharmacol Exp Ther. 2003 Jun; 305(3):1079-86. PMID: 12649308.
      View in: PubMed
    78. Ivie MA, Pollock DA, Gustafson DL, Ivie LL, Rasolomandimby J, Swearingen WD. Field-based evaluation of biopesticide impacts on native biodiversity: malagasy coleoptera and anti-locust entomopathogenic fungi. J Econ Entomol. 2002 Aug; 95(4):651-60. PMID: 12216803.
      View in: PubMed
    79. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002 Jun; 91(6):1488-501. PMID: 12115848.
      View in: PubMed
    Gustafson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)